Home > Boards > US Listed > Medical - Equipment > Guardion Health Sciences Inc. (GHSI)

April 5, 2019 to October 2, 2019 equals

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2004 Member Profile
 
Followed By 19
Posts 2,509
Boards Moderated 0
Alias Born 09/03/17
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 12/10/2019 4:24:02 PM
Guardion Health Sciences, Inc. Reports Results for the Three and Nine Months Ended September 30, 2019 GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 5:27:30 PM
Guardion Health Sciences Closes $8.4 Million Underwritten Public Offering GlobeNewswire Inc. - 10/30/2019 12:33:22 PM
Guardion Health Sciences Announces Pricing of $8.4 Million Underwritten Public Offering GlobeNewswire Inc. - 10/28/2019 9:21:39 AM
Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF GlobeNewswire Inc. - 10/23/2019 7:00:05 AM
Guardion® Announces Statistically Significant Blood Assay Study Results GlobeNewswire Inc. - 10/10/2019 10:30:00 AM
Guardion Health Sciences Acquires the NutriGuard Brand of Products GlobeNewswire Inc. - 9/23/2019 10:30:00 AM
Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test GlobeNewswire Inc. - 9/3/2019 7:00:00 AM
Guardion Health Sciences Closes $5.8 Million Underwritten Public Offering GlobeNewswire Inc. - 8/15/2019 4:05:00 PM
Guardion Health Sciences Announces an Increase in the Pricing of its Previously Announced Underwritten Public Offering GlobeNewswire Inc. - 8/15/2019 8:35:14 AM
Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering GlobeNewswire Inc. - 8/13/2019 9:00:00 AM
Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations GlobeNewswire Inc. - 8/12/2019 8:40:00 AM
Foundation Fighting Blindness selects Guardion’s VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-C... GlobeNewswire Inc. - 8/6/2019 7:00:00 AM
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry GlobeNewswire Inc. - 7/17/2019 7:00:00 AM
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union GlobeNewswire Inc. - 6/20/2019 7:00:00 AM
Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’ GlobeNewswire Inc. - 6/4/2019 7:00:00 AM
Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Functi... GlobeNewswire Inc. - 5/9/2019 10:14:43 AM
Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma GlobeNewswire Inc. - 5/7/2019 7:00:00 AM
Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China GlobeNewswire Inc. - 5/1/2019 7:00:00 AM
Results of Lumega-Z Data to be Presented at ARVO GlobeNewswire Inc. - 4/17/2019 9:01:23 AM
WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services PR Newswire (US) - 4/11/2019 9:18:00 AM
Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering GlobeNewswire Inc. - 4/9/2019 12:20:13 PM
Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering Business Wire - 4/5/2019 12:49:00 PM
H2004   Sunday, 09/29/19 12:15:44 AM
Re: JohnConnor67 post# 287
Post # of 411 
April 5, 2019 to October 2, 2019 equals 180 days.

https://guardionhealth.com/wp-content/uploads/2019/04/tv518316_Guardion_424B4-Prospectus-As-Filed-04-04-19-bannerless.pdf

Answer lies on page 77...

Quote:
SHARES ELIGIBLE FOR FUTURE SALE
Prior to this offering, there has been no public market for the Company’s common stock, and a liquid trading market for its common stock may not develop or be sustained after this offering. Future sales of substantial amounts of the Company’s common stock in the public market, or the anticipation of these sales, could materially and adversely affect market prices prevailing from time to time, and could impair the Company’s ability to raise capital through sales of equity or equity-related securities.

Only a limited number of shares of the Company’s common stock will be available for sale in the public market for a period of several months after completion of this offering due to contractual and legal restrictions on resale described below. Nevertheless, sales of a substantial number of shares of the Company’s common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could materially and adversely affect the prevailing market price of its common stock. Although the Company has applied to list its common stock on the NASDAQ Capital Market, the Company cannot assure you that there will be an active market for its common stock.

Of the shares to be outstanding immediately after the completion of this offering, the Company expects that the 1,250,000 shares to be sold in this offering will be freely tradable without restriction under the Securities Act unless purchased by the Company’s “affiliates,” as that term is defined in Rule 144 under the Securities Act. The Company expects that 18,883,302 of its remaining shares will be subject to the 180-day lock-up period under the lock-up agreements as described below. These restricted securities may be sold in the public market only if the lock-up expires and they are registered or sold pursuant to an exemption from registration, such as Rule 144 or Rule 701 under the Securities Act.

Rule 144

In general, under Rule 144 as currently in effect, once the Company has been subject to the public company reporting requirements of Section 13 or Section 15(d) of the Exchange Act for at least 90 days, a person who is not deemed to have been one of the Company’s affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and who has beneficially owned the shares of its common stock proposed to be sold for at least six months is entitled to sell those shares without complying with the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than Company affiliates, then that person would be entitled to sell those shares without complying with any of the requirements of Rule 144.

In general, under Rule 144, as currently in effect, the Company’s affiliates or persons selling shares of its common stock on behalf of its affiliates are entitled to sell upon expiration of the market standoff agreements and lock-up agreements described above, within any three-month period, a number of shares that does not exceed the greater of:

(a) 1% of the number of shares of the Company’s capital stock then outstanding, which will equal approximately 222,098 shares immediately after this offering; or

(b) the average weekly trading volume of the Company’s common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to that sale.

Sales under Rule 144 by the Company’s affiliates or persons selling shares of its common stock on behalf of its affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about the Company.

Rule 701

Rule 701 generally allows a stockholder who purchased shares of the Company’s common stock pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of the Company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule 144. Rule 701 also permits affiliates of the Company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required to wait until 90 days after the date of this prospectus before selling such shares pursuant to Rule 701 and until expiration of the 180-day lock-up period described below.

Lock-Up Agreements

In connection with this offering, the Company, and its officers, directors and stockholders have agreed to a 180 day "lock-up" period from the closing of this offering, with respect to the shares that they beneficially own, including shares issuable upon the exercise of convertible securities and options that are currently outstanding or which may be issued. This means that, for a period of 180 days following the closing of this offering, such persons may not offer, sell, pledge or otherwise dispose of these securities without the prior written consent of the underwriters. The 180-day restricted period is subject to extension upon certain events and the terms of the lock-up agreements may be waived at the underwriters' discretion. The lock-up restrictions, specified exceptions and the circumstances under which the 180-day lock-up period may be extended are described in more detail under "Underwriting."



Once again, Cheers!!! big smile

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist